Graybug Vision, Inc. (GRAY)
| Market Cap | 17.60M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -34.52M |
| Shares Out | 21.36M |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 87,624 |
| Open | 0.830 |
| Previous Close | 0.844 |
| Day's Range | 0.820 - 0.869 |
| 52-Week Range | 0.720 - 7.060 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 3.19 (+287.2%) |
| Earnings Date | Aug 10, 2022 |
About GRAY
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, a... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for GRAY stock is "Buy." The 12-month stock price forecast is 3.19, which is an increase of 287.23% from the latest price.
News
Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting
BALTIMORE, May 19, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular dis...
Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting
BALTIMORE, April 27, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...
Graybug to Present at the 2022 ASCRS Annual Meeting
BALTIMORE, April 18, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...
Graybug Vision Appoints Dirk Sauer to Board of Directors
BALTIMORE, April 13, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...
Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023
BALTIMORE, March 30, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...
Graybug Vision to Host Virtual R&D Day on March 30, 2022
BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular d...
Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments
Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET Management to host R&D Day for investors on March 30, 2022 at 11 a.m. ET
Graybug to Participate in Three Upcoming Medical and Investor Conferences
BALTIMORE, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...
Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline
BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...
Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corpora...
BALTIMORE, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases ...
Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference
BALTIMORE, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...
Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD
BALTIMORE, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...
Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference
BALTIMORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases...
Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Dev...
REDWOOD CITY, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...
Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference
REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment o...
Is the Options Market Predicting a Spike in Graybug Vision (GRAY) Stock?
Investors need to pay close attention to Graybug Vision (GRAY) stock based on the movements in the options market lately.
Graybug Vision Shorts Got A Serious Squeeze: What's Next?
Graybug Vision Inc (NASDAQ: GRAY) has not released any news since it printed its first-quarter 2021 earnings results May 12, but that didn't stop the stock from closing up 22% on Thursday and soaring fu...
Graybug Vision Reports Full Data Analysis After One Year Treatment Of GB-102 In Wet AMD
Graybug Vision Inc (NASDAQ: GRAY) has provided full-data analysis from the 12-month treatment Phase of its Phase 2b ALTISSIMO trial evaluating GB-102 to treat wet age-related macular degeneration (wet A...
Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Why Is Graybug Vision Stock Plunging Today?
Graybug Vision Inc (NASDAQ: GRAY) shares are dropping after preliminary data from Phase 2b ALTISSIMO trial of GB-102 for wet age-related macular degeneration (wet AMD). Investors are reacting to the mea...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment ...
Graybug Vision to Participate in SVB Leerink Global Healthcare Conference
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company's Executive Team
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat chronic vi...